Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Further strengthens BaseLaunch's global pharma industry partnerships
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Subscribe To Our Newsletter & Stay Updated
